EGFR amplification and EGFR variant III (EGFRvIII), which is characterized by the deletion of exons 2–7, are the two most frequent EGFR alterations in glioblastoma observed in 40–50% and 10% of patients, respectively [4–7]. Here, EGFR is linked to glioblastoma.